心肌梗死后停用β受体阻滞剂
该开放标签、随机、非劣效性试验在韩国25个中心纳入2540例心肌梗死后病情稳定、左室射血分数至少40%、无心力衰竭且已接受β受体阻滞剂治疗至少1年的患者,1:1随机分为停用组(1246例)与继续组(1294例)。主要终点为全因死亡、再发心肌梗死或心力衰竭住院的复合终点。中位随访3.1年时,停用组58例发生主要终点事件(4年Kaplan-Meier估计7.2%),继续组74例(4年估计9.0%),风险比0.80(95%CI 0.57-1.13),非劣效性检验P=0.001。两组严重不良事件发生率相似。
要点
- 纳入标准:心肌梗死后病情稳定、左室射血分数至少40%、无心力衰竭、已接受β受体阻滞剂至少1年。
- 停用组主要终点事件58例(4年Kaplan-Meier估计7.2%)vs 继续组74例(9.0%),风险比0.80(95%CI 0.57-1.13),非劣效性P=0.001。
- 非劣效性界限预设为风险比95%CI上限1.4。
- 两组严重不良事件发生率相似。
- 中位随访3.1年(四分位距2.5至3.5年)。
适用人群与场景
- 心肌梗死后病情稳定、左室射血分数至少40%、无心力衰竭、已接受β受体阻滞剂治疗至少1年的患者。
- 韩国25个中心纳入的成人患者,平均年龄63.2岁,女性占12.8%。
诊断标准与关键阈值
- 非劣效性界限:风险比95%置信区间上限为1.4。
研究设计与关键结果
- 开放标签、随机、非劣效性试验,在韩国25个中心进行,共2540例患者随机分组:停用组1246例,继续组1294例。
- 主要终点为全因死亡、再发心肌梗死或心力衰竭住院的复合终点;中位随访3.1年(四分位距2.5至3.5年)。
- 停用组主要终点事件58例(4年Kaplan-Meier估计7.2%)vs 继续组74例(4年Kaplan-Meier估计9.0%),风险比0.80(95%CI 0.57-1.13),非劣效性P=0.001。
- 两组严重不良事件发生率相似。
证据类型、等级与局限
- 证据类型:开放标签、随机、非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于心肌梗死后左室射血分数至少40%、无心力衰竭且已接受β受体阻滞剂至少1年的稳定患者,停用β受体阻滞剂在主要复合终点上非劣于继续用药。
- 该结论不适用于左室射血分数低于40%或合并心力衰竭的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary coronary-artery reperfusion and secondary prevention interventions.
METHODS: We conducted an open-label, randomized, noninferiority trial at 25 centers in South Korea. Patients whose condition remained stable after a myocardial infarction, who had a left ventricular ejection fraction of at least 40% and no heart failure, and who had received beta-blocker therapy for at least 1 year after the myocardial infarction were randomly assigned in a 1:1 ratio to discontinue or to continue beta-blocker therapy. The primary end point was a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure. The prespecified noninferiority margin was an upper limit of the 95% confidence interval for the hazard ratio of 1.4.
RESULTS: A total of 2540 patients underwent randomization; 1246 were assigned to beta-blocker discontinuation and 1294 to beta-blocker continuation. The mean age of the patients was 63.2 years, and 12.8% were women. At a median follow-up of 3.1 years (interquartile range, 2.5 to 3.5), a primary end-point event had occurred in 58 patients (4-year Kaplan-Meier estimate, 7.2%) in the discontinuation group and in 74 patients (4-year Kaplan-Meier estimate, 9.0%) in the continuation group (hazard ratio, 0.80; 95% confidence interval, 0.57 to 1.13; P = 0.001 for noninferiority). The incidence of serious adverse events was similar in the two groups.
CONCLUSIONS: Among patients who received beta-blocker therapy beyond the first year after a myocardial infarction, discontinuation of beta-blocker therapy was noninferior to continuation with respect to a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure. (Funded by Patient-Centered Clinical Research Coordinating Center in the Ministry of Health and Welfare, South Korea; SMART-DECISION ClinicalTrials.gov number, NCT04769362.).
参考来源
- Choi KH, Kang D, Kim W, et al. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. N Engl J Med. 2026. PMID: 41910427. doi:10.1056/NEJMoa2601005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。